Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide for Reducing Recurrence After Catheter Ablation in Obese Patients With Atrial Fibrillation
NCT07897305Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of mazdutide in Atrial fibrillation (AFib) and obesity (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Recurrence of atrial arrhythmias without the use of any Class I/III antiarrhythmic drugs (AADs) at 12 months and Composite serious adverse events (SAEs) at 52 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
Atrial fibrillation (AFib)obesity
Beyond the preview
Go deeper on NCT07897305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897305.